Fulcrum Therapeutics (FULC) Net Equity Issued and Repurchased (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Net Equity Issued and Repurchased of $356000.0 for Q2 2026, up 18.27% year-over-year from $301000.0 in Q2 2025, and up 1595.24% quarter-over-quarter from $21000.0 in Q1 2026.
Fulcrum Therapeutics (FULC) Net Equity Issued and Repurchased (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Net Equity Issued and Repurchased for 9 consecutive years, with $356000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Equity Issued and Repurchased rose 18.27% year-over-year to $356000.0; the TTM figure through Jun 2026 stood at $4.2 million (up 316.39% YoY), while the FY2025 annual figure was $4.2 million, up 51.75% from the prior year.
- Net Equity Issued and Repurchased grew to $356000.0 in Q2 2026 per FULC's latest filing, from $21000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $3.8 million in Q4 2025 and bottomed at $21000.0 in Q1 2026.
- Historically, Net Equity Issued and Repurchased has averaged $724125.0 across 5 years, with a median of $324500.0 in 2022.
- Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased sank 96.08% — and 2025, when it jumped 4480.72%.
- Fulcrum Therapeutics' Net Equity Issued and Repurchased stood at $267000.0 in 2022, then rose by 7.49% to $287000.0 in 2023, then slumped by 71.08% to $83000.0 in 2024, then surged by 4480.72% to $3.8 million in 2025, then slumped by 90.64% to $356000.0 in 2026.
- Business Quant data shows FULC's Net Equity Issued and Repurchased at $356000.0 in Q2 2026, $21000.0 in Q1 2026, and $3.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | 356,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 356,000.00 |
| Jun 30, 2026 | 356,000.00 |
| Mar 31, 2026 | 21,000.00 |
| Mar 31, 2026 | 21,000.00 |
| Dec 31, 2025 | 3.80 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Sep 30, 2025 | 64,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Jun 30, 2025 | 301,000.00 |
| Jun 30, 2025 | 301,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Sep 30, 2024 | 635,000.00 |
| Sep 30, 2024 | 635,000.00 |
| Jun 30, 2024 | 377,000.00 |
| Jun 30, 2024 | 377,000.00 |
| Mar 31, 2024 | 1.65 Mn |
| Mar 31, 2024 | 1.65 Mn |
| Dec 31, 2023 | 287,000.00 |
| Dec 31, 2023 | 287,000.00 |